Wart war: two injections face off in plantar wart study
NCT ID NCT07197541
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests two injected medications, bleomycin and pingyangmycin, for treating plantar warts. Each of the 200 adult participants will receive both drugs on different warts to compare which works better. The main goal is complete clearing of the warts, with follow-up for 36 weeks to check for return of the warts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Aged over 18 years old; 2. Clinical diagnosis of plantar warts; 3. The diameter of a single wart is ≥1cm, and the number is ≥2; 4. There is a history of other treatments for plantar warts within 4 weeks, including drugs and physical therapy; 5. Have a basic understanding of the purpose, effects and possible adverse reactions of the trial, and sign an informed consent form in accordance with the spirit of the Declaration of Helsinki. Exclusion Criteria: 1. There are other local infections in the treatment area and injection is not suitable; 2. Patients allergic to lidocaine, bleomycin, and pingyangmycin; 3. Patients with other serious skin diseases, tumors or other systemic diseases; 4. Patients with infections such as tuberculosis, HIV, hepatitis B, hepatitis C; 5. Patients with a history of other treatments for plantar warts in the previous 4 weeks, including drugs and physical therapy; 6. Patients who have participated in other clinical trials in the past 3 months; 7. Pregnant women, lactating women, or patients who plan to become pregnant during the trial; 8. Those who have any history of major surgery in the previous 8 weeks or who may have surgery planned during treatment; 9. Patients with a history of mental illness.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Plantar wart are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The second Affiliated hospital of Zhejiang university school of medicine
Hangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.